Potential Drugs in COVID-19 Management


Дәйексөз келтіру

Толық мәтін

Аннотация

The SARS-CoV-2 virus first emerged in China in December 2019 and quickly spread worldwide. Despite the absence of a vaccination or authorized drug specifically developed to combat this infection, certain medications recommended for other diseases have shown potential effectiveness in treating COVID-19, although without definitive confirmation. This review aims to evaluate the existing literature on the efficacy of these medications against COVID-19. The review encompasses various potential treatments, including antiviral medications, anti-malaria and anti-rheumatic drugs, vaccines, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antipyretic and analgesic medicines, antiparasitic drugs, and statins. The analysis also addresses the potential benefits and drawbacks of these medications, as well as their effects on hypertension and diabetes. Although these therapies hold promise against COVID-19, further research, including suitable product production or clinical testing, is needed to establish their therapeutic efficacy.

Авторлар туралы

Amin Gasmi

, Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée

Email: info@benthamscience.net

Sadaf Noor

Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University

Email: info@benthamscience.net

Alain Menzel

, Laboratoires Réunis

Email: info@benthamscience.net

Nataliia Khanyk

, Danylo Halytsky Lviv National Medical University

Email: info@benthamscience.net

Yuliya Semenova

School of Medicine, Nazarbayev University

Email: info@benthamscience.net

Roman Lysiuk

, Danylo Halytsky Lviv National Medical University

Email: info@benthamscience.net

Nataliya Beley

, I. Ya. Horbachevsky Ternopil National Medical University

Email: info@benthamscience.net

Liliia Bolibrukh

, Lviv Polytechnic National University

Email: info@benthamscience.net

Asma Gasmi Benahmed

, Académie Internationale de Médecine Dentaire Intégrative

Email: info@benthamscience.net

Olha Storchylo

Medical Chemistry Department,, Odessa National Medical University

Email: info@benthamscience.net

Geir Bjørklund

, Council for Nutritional and Environmental Medicine (CONEM)

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 2020, 395(10229), 1054-1062. doi: 10.1016/S0140-6736(20)30566-3 PMID: 32171076
  2. Wu, Z.; McGoogan, J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13), 1239-1242. doi: 10.1001/jama.2020.2648 PMID: 32091533
  3. Mahase, E. Long covid could be four different syndromes, review suggests. BMJ, 2020, 371, m3981. doi: 10.1136/bmj.m3981 PMID: 33055076
  4. Liu, J.; Liu, Y.; Xiang, P.; Pu, L.; Xiong, H.; Li, C.; Zhang, M.; Tan, J.; Xu, Y.; Song, R. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. J. Transl. Med., 2020, 18(1), 206. doi: 10.1186/s12967-020-02374-0 PMID: 32434518
  5. Cao, Q.; Chen, Y.C.; Chen, C.L.; Chiu, C.H. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J. Formos. Med. Assoc., 2020, 119(3), 670-673. doi: 10.1016/j.jfma.2020.02.009 PMID: 32139299
  6. Peiris, J.S.M.; Chu, C.M.; Cheng, V.C.C.; Chan, K.S.; Hung, I.F.N.; Poon, L.L.M.; Law, K.I.; Tang, B.S.F.; Hon, T.Y.W.; Chan, C.S.; Chan, K.H.; Ng, J.S.C.; Zheng, B.J.; Ng, W.L.; Lai, R.W.M.; Guan, Y.; Yuen, K.Y. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet, 2003, 361(9371), 1767-1772. doi: 10.1016/S0140-6736(03)13412-5 PMID: 12781535
  7. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223), 507-513. doi: 10.1016/S0140-6736(20)30211-7 PMID: 32007143
  8. Huang, W.H.; Teng, L.C.; Yeh, T.K.; Chen, Y.J.; Lo, W.J.; Wu, M.J.; Chin, C.S.; Tsan, Y.T.; Lin, T.C.; Chai, J.W.; Lin, C.F.; Tseng, C.H.; Liu, C.W.; Wu, C.M.; Chen, P.Y.; Shi, Z.Y.; Liu, P.Y. 2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. J. Microbiol. Immunol. Infect., 2020, 53(3), 481-484. doi: 10.1016/j.jmii.2020.02.009 PMID: 32111449
  9. Lee, P.I.; Hu, Y.L.; Chen, P.Y.; Huang, Y.C.; Hsueh, P.R. Are children less susceptible to COVID-19? J. Microbiol. Immunol. Infect., 2020, 53(3), 371-372. doi: 10.1016/j.jmii.2020.02.011 PMID: 32147409
  10. Zamorano Cuervo, N.; Grandvaux, N. ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. eLife, 2020, 9, e61390. doi: 10.7554/eLife.61390 PMID: 33164751
  11. Ni, W.; Yang, X.; Yang, D.; Bao, J.; Li, R.; Xiao, Y.; Hou, C.; Wang, H.; Liu, J.; Yang, D.; Xu, Y.; Cao, Z.; Gao, Z. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care, 2020, 24(1), 422. doi: 10.1186/s13054-020-03120-0 PMID: 32660650
  12. Hofmann, H.; Pyrc, K.; van der Hoek, L.; Geier, M.; Berkhout, B.; Pöhlmann, S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci., 2005, 102(22), 7988-7993. doi: 10.1073/pnas.0409465102 PMID: 15897467
  13. Lee, K.H.; Yoo, S.G.; Cho, Y.; Kwon, D.E.; La, Y.; Han, S.H.; Kim, M.S.; Choi, J.S.; Kim, S.I.; Kim, Y.S.; Min, Y.H.; Cheong, J.W.; Kim, J.S.; Song, Y.G. Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients. J. Microbiol. Immunol. Infect., 2021, 54(2), 253-260. doi: 10.1016/j.jmii.2019.05.007 PMID: 31262511
  14. Lee, P.I.; Hsueh, P.R. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J. Microbiol. Immunol. Infect., 2020, 53(3), 365-367. doi: 10.1016/j.jmii.2020.02.001 PMID: 32035811
  15. To, K.K.W.; Tsang, O.T.Y.; Leung, W.S.; Tam, A.R.; Wu, T.C.; Lung, D.C.; Yip, C.C.Y.; Cai, J.P.; Chan, J.M.C.; Chik, T.S.H.; Lau, D.P.L.; Choi, C.Y.C.; Chen, L.L.; Chan, W.M.; Chan, K.H.; Ip, J.D.; Ng, A.C.K.; Poon, R.W.S.; Luo, C.T.; Cheng, V.C.C.; Chan, J.F.W.; Hung, I.F.N.; Chen, Z.; Chen, H.; Yuen, K.Y. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect. Dis., 2020, 20(5), 565-574. doi: 10.1016/S1473-3099(20)30196-1 PMID: 32213337
  16. Peeri, N.C.; Shrestha, N.; Rahman, M.S.; Zaki, R.; Tan, Z.; Bibi, S.; Baghbanzadeh, M.; Aghamohammadi, N.; Zhang, W.; Haque, U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: What lessons have we learned? Int. J. Epidemiol., 2020, 49(3), 717-726. doi: 10.1093/ije/dyaa033 PMID: 32086938
  17. Semenova, Y.; Trenina, V.; Pivina, L.; Glushkova, N.; Zhunussov, Y.; Ospanov, E.; Bjørklund, G. The lessons of COVID-19, SARS, and MERS: Implications for preventive strategies. Int. J. Healthc. Manag., 2022, 15(4), 314-324. doi: 10.1080/20479700.2022.2051126
  18. Lui, G.; Guaraldi, G. Drug treatment of COVID-19 infection. Curr. Opin. Pulm. Med., 2023, 29(3), 174-183. doi: 10.1097/MCP.0000000000000953 PMID: 36917228
  19. Yuan, Y.; Jiao, B.; Qu, L.; Yang, D.; Liu, R. The development of COVID-19 treatment. Front. Immunol., 2023, 14, 1125246. doi: 10.3389/fimmu.2023.1125246 PMID: 36776881
  20. Chu, C.M.; Cheng, V.C.; Hung, I.F.; Wong, M.M.; Chan, K.H.; Chan, K.S.; Kao, R.Y.; Poon, L.L.; Wong, C.L.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax, 2004, 59(3), 252-256. doi: 10.1136/thorax.2003.012658 PMID: 14985565
  21. Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med., 2020, 382(19), 1787-1799. doi: 10.1056/NEJMoa2001282 PMID: 32187464
  22. Lim, J.; Jeon, S.; Shin, H-Y.; Kim, M.J.; Seong, Y.M.; Lee, W.J.; Choe, K-W.; Kang, Y.M.; Lee, B.; Park, S-J. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci., 2020, 35(6), e79. doi: 10.3346/jkms.2020.35.e79 PMID: 32056407
  23. Kim, U.J.; Won, E.J.; Kee, S.J.; Jung, S.I.; Jang, H.C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir. Ther., 2016, 21(5), 455-459. doi: 10.3851/IMP3002 PMID: 26492219
  24. Rosa, S.G.V.; Santos, W.C. Clinical trials on drug repositioning for COVID-19 treatment. Rev. Panam. Salud Publica, 2020, 44, 1. doi: 10.26633/RPSP.2020.40 PMID: 32256547
  25. Dong, L.; Hu, S.; Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther., 2020, 14(1), 58-60. doi: 10.5582/ddt.2020.01012 PMID: 32147628
  26. Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.; Shen, C.; Li, X.; Peng, L.; Huang, D.; Zhang, J.; Zhang, S.; Wang, F.; Liu, J.; Chen, L.; Chen, S.; Wang, Z.; Zhang, Z.; Cao, R.; Zhong, W.; Liu, Y.; Liu, L. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering, 2020, 6(10), 1192-1198. doi: 10.1016/j.eng.2020.03.007 PMID: 32346491
  27. Cyranoski, D.; Abbott, A. Virus detectives seek source of SARS in China’s wild animals. Nature, 2003, 423(6939), 467. doi: 10.1038/423467a PMID: 12774078
  28. Morgenstern, B.; Michaelis, M.; Baer, P.C.; Doerr, H.W.; Cinatl, J., Jr Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Commun., 2005, 326(4), 905-908. doi: 10.1016/j.bbrc.2004.11.128 PMID: 15607755
  29. Khalili, J.S.; Zhu, H.; Mak, N.S.A.; Yan, Y.; Zhu, Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J. Med. Virol., 2020, 92(7), 740-746. doi: 10.1002/jmv.25798 PMID: 32227493
  30. Elfiky, A.A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci., 2020, 253, 117592. doi: 10.1016/j.lfs.2020.117592 PMID: 32222463
  31. Holshue, M.L.; DeBolt, C.; Lindquist, S.; Lofy, K.H.; Wiesman, J.; Bruce, H.; Spitters, C.; Ericson, K.; Wilkerson, S.; Tural, A.; Diaz, G.; Cohn, A.; Fox, L.; Patel, A.; Gerber, S.I.; Kim, L.; Tong, S.; Lu, X.; Lindstrom, S.; Pallansch, M.A.; Weldon, W.C.; Biggs, H.M.; Uyeki, T.M.; Pillai, S.K. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med., 2020, 382(10), 929-936. doi: 10.1056/NEJMoa2001191 PMID: 32004427
  32. Agostini, M.L.; Andres, E.L.; Sims, A.C.; Graham, R.L.; Sheahan, T.P.; Lu, X.; Smith, E.C.; Case, J.B.; Feng, J.Y.; Jordan, R.; Ray, A.S.; Cihlar, T.; Siegel, D.; Mackman, R.L.; Clarke, M.O.; Baric, R.S.; Denison, M.R. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio, 2018, 9(2), e00221-18. doi: 10.1128/mBio.00221-18 PMID: 29511076
  33. Lim, S.Y.; Guo, Z.; Liu, P.; McKay, L.G.A.; Storm, N.; Griffiths, A.; Qu, M.D.; Finberg, R.W.; Somasundaran, M.; Wang, J.P. Anti-SARS-CoV-2 activity of adamantanes in vitro and in animal models of infection. COVID, 2022, 2(11), 1551-1563. doi: 10.3390/covid2110111 PMID: 37274537
  34. deVries, T.; Dentiste, A.; Handiwala, L.; Jacobs, D. Bioavailability and pharmacokinetics of once-daily amantadine extended-release tablets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies. Neurol. Ther., 2019, 8(2), 449-460. doi: 10.1007/s40120-019-0144-1 PMID: 31372936
  35. Zhou, Y.; Gammeltoft, K.A.; Galli, A.; Offersgaard, A.; Fahnøe, U.; Ramirez, S.; Bukh, J.; Gottwein, J.M. Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. Viruses, 2021, 13(10), 2082. doi: 10.3390/v13102082 PMID: 34696509
  36. Rejdak, K.; Fiedor, P.; Bonek, R.; Goch, A.; Gala-Błądzińska, A.; Chełstowski, W.; Łukasiak, J.; Kiciak, S.; Dąbrowski, P.; Dec, M.; Król, Z.J.; Papuć, E.; Zasybska, A.; Segiet, A.; Grieb, P. The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design. Contemp. Clin. Trials, 2022, 116, 106755. doi: 10.1016/j.cct.2022.106755 PMID: 35390511
  37. Barczyk, A.; Czajkowska-Malinowska, M.; Farnik, M.; Barczyk, M.; Boda, Ł.; Cofta, S.; Duława, J.; Dyrbuś, M.; Harat, R.; Huk, M.; Kotecka, S.; Nahorecki, A.; Nasiłowski, J.; Naumnik, W.; Przybylski, G.; Słaboń-Willand, M.; Skoczyński, S.; Wita, K.; Zioło, G.; Kuna, P. Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study. Respir. Med., 2023, 212, 107198. doi: 10.1016/j.rmed.2023.107198 PMID: 36931576
  38. Keyser, L.A.; Karl, M.; Nafziger, A.N.; Bertino, J.S., Jr Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch. Intern. Med., 2000, 160(10), 1485-1488. doi: 10.1001/archinte.160.10.1485 PMID: 10826462
  39. Hayden, F.G.; Hoffman, H.E.; Spyker, D.A. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob. Agents Chemother., 1983, 23(3), 458-464. doi: 10.1128/AAC.23.3.458 PMID: 6847173
  40. Touret, F.; de Lamballerie, X. Of chloroquine and COVID-19. Antiviral Res., 2020, 177, 104762. doi: 10.1016/j.antiviral.2020.104762 PMID: 32147496
  41. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271. doi: 10.1038/s41422-020-0282-0 PMID: 32020029
  42. Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, 2(1), 69. doi: 10.1186/1743-422X-2-69 PMID: 16115318
  43. Boulware, D.R.; Pullen, M.F.; Bangdiwala, A.S.; Pastick, K.A.; Lofgren, S.M.; Okafor, E.C.; Skipper, C.P.; Nascene, A.A.; Nicol, M.R.; Abassi, M.; Engen, N.W.; Cheng, M.P.; LaBar, D.; Lother, S.A.; MacKenzie, L.J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L.E.; Schwartz, I.S.; McDonald, E.G.; Rajasingham, R.; Lee, T.C.; Hullsiek, K.H. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Engl. J. Med., 2020, 383(6), 517-525. doi: 10.1056/NEJMoa2016638 PMID: 32492293
  44. Bhimraj, A.; Morgan, R.L.; Shumaker, A.H.; Baden, L.; Cheng, V.C.C.; Edwards, K.M.; Gallagher, J.C.; Gandhi, R.T.; Muller, W.J.; Nakamura, M.M.; O’Horo, J.C.; Shafer, R.W.; Shoham, S.; Murad, M.H.; Mustafa, R.A.; Sultan, S.; Falck-Ytter, Y. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin. Infect. Dis., 2022, ciac724. doi: 10.1093/cid/ciac724 PMID: 36063397
  45. Luo, P.; Liu, Y.; Qiu, L.; Liu, X.; Liu, D.; Li, J. Tocilizumab treatment in COVID-19: A single center experience. J. Med. Virol., 2020, 92(7), 814-818. doi: 10.1002/jmv.25801 PMID: 32253759
  46. Stone, J.H.; Frigault, M.J.; Serling-Boyd, N.J.; Fernandes, A.D.; Harvey, L.; Foulkes, A.S.; Horick, N.K.; Healy, B.C.; Shah, R.; Bensaci, A.M.; Woolley, A.E.; Nikiforow, S.; Lin, N.; Sagar, M.; Schrager, H.; Huckins, D.S.; Axelrod, M.; Pincus, M.D.; Fleisher, J.; Sacks, C.A.; Dougan, M.; North, C.M.; Halvorsen, Y.D.; Thurber, T.K.; Dagher, Z.; Scherer, A.; Wallwork, R.S.; Kim, A.Y.; Schoenfeld, S.; Sen, P.; Neilan, T.G.; Perugino, C.A.; Unizony, S.H.; Collier, D.S.; Matza, M.A.; Yinh, J.M.; Bowman, K.A.; Meyerowitz, E.; Zafar, A.; Drobni, Z.D.; Bolster, M.B.; Kohler, M.; D’Silva, K.M.; Dau, J.; Lockwood, M.M.; Cubbison, C.; Weber, B.N.; Mansour, M.K. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med., 2020, 383(24), 2333-2344. doi: 10.1056/NEJMoa2028836 PMID: 33085857
  47. Salvarani, C.; Dolci, G.; Massari, M.; Merlo, D.F.; Cavuto, S.; Savoldi, L.; Bruzzi, P.; Boni, F.; Braglia, L.; Turrà, C.; Ballerini, P.F.; Sciascia, R.; Zammarchi, L.; Para, O.; Scotton, P.G.; Inojosa, W.O.; Ravagnani, V.; Salerno, N.D.; Sainaghi, P.P.; Brignone, A.; Codeluppi, M.; Teopompi, E.; Milesi, M.; Bertomoro, P.; Claudio, N.; Salio, M.; Falcone, M.; Cenderello, G.; Donghi, L.; Del Bono, V.; Colombelli, P.L.; Angheben, A.; Passaro, A.; Secondo, G.; Pascale, R.; Piazza, I.; Facciolongo, N.; Costantini, M. Effect of tocilizumab vs. standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern. Med., 2021, 181(1), 24-31. doi: 10.1001/jamainternmed.2020.6615 PMID: 33080005
  48. Hermine, O.; Mariette, X.; Tharaux, P.L.; Resche-Rigon, M.; Porcher, R.; Ravaud, P.; Bureau, S.; Dougados, M.; Tibi, A.; Azoulay, E.; Cadranel, J.; Emmerich, J.; Fartoukh, M.; Guidet, B.; Humbert, M.; Lacombe, K.; Mahevas, M.; Pene, F.; Pourchet-Martinez, V.; Schlemmer, F.; Yazdanpanah, Y.; Baron, G.; Perrodeau, E.; Vanhoye, D.; Kedzia, C.; Demerville, L.; Gysembergh-Houal, A.; Bourgoin, A.; Dalibey, S.; Resche-Rigon, M.; Raked, N.; Mameri, L.; Alary, S.; Hamiria, S.; Bariz, T.; Semri, H.; Hai, D.M.; Benafla, M.; Belloul, M.; Vauboin, P.; Flamand, S.; Pacheco, C.; Walter-Petrich, A.; Stan, E.; Benarab, S.; Nyanou, C.; Montlahuc, C.; Biard, L.; Charreteur, R.; Dupré, C.; Cardet, K.; Lehmann, B.; Baghli, K.; Madeleine, C.; D’Ortenzio, E.; Puéchal, O.; Semaille, C.; Savale, L.; Harrois, A.; Figueiredo, S.; Duranteau, J.; Anguel, N.; Monnet, X.; Richard, C.; Teboul, J-L.; Durand, P.; Tissieres, P.; Jevnikar, M.; Montani, D.; Pavy, S.; Noel, N.; Lambotte, O.; Escaut, L.; Jauréguiberry, S.; Baudry, E.; Verny, C.; Lefèvre, E.; Zaidan, M.; Le Tiec, C.L.T.; Verstuyft, C.V.; Roques, A-M.; Grimaldi, L.; Molinari, D.; Leprun, G.; Fourreau, A.; Cylly, L.; Virlouvet, M.; Meftali, R.; Fabre, S.; Licois, M.; Mamoune, A.; Boudali, Y.; Georgin-Lavialle, S.; Senet, P.; Soria, A.; Parrot, A.; François, H.; Rozensztajn, N.; Blin, E.; Choinier, P.; Camuset, J.; Rech, J-S.; Canellas, A.; Rolland-Debord, C.; Lemarié, N.; Belaube, N.; Nadal, M.; Siguier, M.; Petit-Hoang, C.; Chas, J.; Drouet, E.; Lemoine, M.; Phibel, A.; Aunay, L.; Bertrand, E.; Ravato, S.; Vayssettes, M.; Adda, A.; Wilpotte, C.; Thibaut, P.; Fillon, J.; Debrix, I.; Fellahi, S.; Bastard, J-P.; Lefèvre, G.; Fallet, V.; Gottenberg, J-E.; Hansmann, Y.; Andres, E.; Bayer, S.; Becker, G.; Blanc, F.; Brin, S.; Castelain, V.; Chatelus, E.; Chatron, E.; Collange, O.; Danion, F.; De Blay, F.; Demonsant, E.; Diemunsch, P.; Diemunsch, S.; Felten, R.; Goichot, B.; Greigert, V.; Guffroy, A.; Heger, B.; Hutt, A.; Kaeuffer, C.; Kassegne, L.; Korganow, A.S.; Le Borgne, P.; Lefebvre, N.; Martin, T.; Mertes, P.M.; Metzger, C.; Meyer, N.; Nisand, G.; Noll, E.; Oberlin, M.; Ohlmann-Caillard, S.; Poindron, V.; Pottecher, J.; Ruch, Y.; Sublon, C.; Tayebi, H.; Weill, F.; Mekinian, A.; Chopin, D.; Fain, O.; Garnier, M.; Krause Le Garrec, J.; Morgand, M.; Pacanowski, J.; Urbina, T.; Mcavoy, C.; Pereira, M.; Aratus, G.; Berard, L.; Simon, T.; Daguenel Nguyen, A.; Antignac, M.; Leplay, C.; Arlet, J-B.; Diehl, J-L.; Bellenfant, F.; Blanchard, A.; Buffet, A.; Cholley, B.; Fayol, A.; Flamarion, E.; Godier, A.; Gorget, T.; Hamada, S-R.; Hauw-Berlemont, C.; Hulot, J-S.; Lebeaux, D.; Livrozet, M.; Michon, A.; Neuschwander, A.; Penet, M-A.; Planquette, B.; Ranque, B.; Sanchez, O.; Volle, G.; Briois, S.; Cornic, M.; Elisee, V.; Jesuthasan, D.; Djadi-Prat, J.; Jouany, P.; Junquera, R.; Henriques, M.; Kebir, A.; Lehir, I.; Meunier, J.; Patin, F.; Paquet, V.; TréHan, A.; Vigna, V.; Sabatier, B.; Bergerot, D.; Jouve, C.; Knosp, C.; Lenoir, O.; Mahtal, N.; Resmini, L.; Lescure, X.; Ghosn, J.; Bachelard, A.; Bironne, T.; Borie, R.; Bounhiol, A.; Boussard, C.; Chauffier, J.; Chalal, S.; Chalal, L.; Chansombat, M.; Crespin, P.; Crestani, B.; Daconceicao, O.; Deconinck, L.; Dieude; Dossier, A.; Dubert, M.; Ducrocq, G.; Fuentes, A.; Gervais, A.; Gilbert, M.; Isernia, V.; Ismael, S.; Joly, V.; Julia, Z.; Lariven, S.; Le Gac, S.; Le Pluart, D.; Louni, F.; Ndiaye, A.; Papo, T.; Parisey, M.; Phung, B.; Pourbaix, A.; Rachline, A.; Rioux, C.; Sautereau, A.; Steg, G.; Tharini, H.; Valayer, S.; Vallois, D.; Vermes, P.; Volpe, T.; Nguyen, Y.; Honsel, V.; Weiss, E.; Codorniu, A.; Zarrouk, V.; De Lastours, V.; Uzzan, M.; Gamany, N.; Rahli, R.; Louis, Z.; Boutboul, D.; Galicier, L.; Amara, Y.; Archer, G.; Benattia, A.; Bergeron, A.; Bondeelle, L.; De Castro, N.; Clément, M.; Darmont, M.; Denis, B.; Dupin, C.; Feredj, E.; Feyeux, D.; Joseph, A.; Lengliné, E.; Le Guen, P.; Liégeon, G.; Lorillon, G.; Mabrouki, A.; Mariotte, E.; Martin De Frémont, G.; Mirouse, A.; Molina, J-M.; Peffault De Latour, R.; Oksenhendler, E.; Saussereau, J.; Tazi, A.; Tudesq, J-J.; Zafrani, L.; Brindele, I.; Bugnet, E.; Celli Lebras, K.; Chabert, J.; Djaghout, L.; Fauvaux, C.; Jegu, A.L.; Kozaliewicz, E.; Meunier, M.; Tremorin, M-T.; Davoine, C.; Madeleine, I.; Caillat-Zucman, S.; Delaugerre, C.; Morin, F.; Sene, D.; Burlacu, R.; Chousterman, B.; Megarbane, B.; Richette, P.; Riveline, J-P.; Frazier, A.; Vicaut, E.; Berton, L.; Hadjam, T.; Vasquez-Ibarra, M.A.; Jourdaine, C.; Jacob, A.; Smati, J.; Renaud, S.; Manivet, P.; Pernin, C.; Suarez, L.; Semerano, L.; Abad, S.; Benainous, R.; Bloch Queyrat, C.; Bonnet, N.; Brahmi, S.; Cailhol; Cohen, Y.; Comparon, C.; Cordel, H.; Dhote, R.; Dournon, N.; Duchemann, B.; Ebstein, N.; Giroux-Leprieur, B.; Goupil De Bouille, J.; Jacolot, A.; Nunes, H.; Oziel, J.; Rathouin, V.; Rigal, M.; Roulot, D.; Tantet, C.; Uzunhan, Y.; Costedoat-Chalumeau, N.; Ait Hamou, Z.; Benghanem, S.; Blanche, P.; Canoui, E.; Carlier, N.; Chaigne, B.; Contejean, A.; Dunogue, B.; Dupland, P.; Durel - Maurisse, A.; Gauzit, R.; Jaubert, P.; Joumaa, H.; Jozwiak, M.; Kerneis, S.; Lachatre, M.; Lafoeste, H.; Legendre, P.; Luong Nguyen, L.B.; Marey, J.; Morbieu, C.; Mouthon, L.; Nguyen, L.; Palmieri, L-J.; Regent, A.; Szwebel, T-A.; Terrier, B.; Guerin, C.; Zerbit, J.; Cheref, K.; Chitour, K.; Cisse, M.S.; Clarke, A.; Clavere, G.; Dusanter, I.; Gaudefroy, C.; Jallouli, M.; Kolta, S.; Le Bourlout, C.; Marin, N.; Menage, N.; Moores, A.; Peigney, I.; Pierron, C.; Saleh-Mghir, S.; Vallet, M.; Michel, M.; Melica, G.; Lelievre, J-D.; Fois, E.; Lim, P.; Matignon, M.; Guillaud, C.; Thiemele, A.; Schmitz, D.; Bouhris, M.; Belazouz, S.; Languille, L.; Mekontso-Dessaps, A.; Sadaoui, T.; Mayaux, J.; Cacoub, P.; Corvol, J-C.; Louapre, C.; Sambin, S.; Mariani, L-L.; Karachi, C.; Tubach, F.; Estellat, C.; Gimeno, L.; Martin, K.; Bah, A.; Keo, V.; Ouamri, S.; Messaoudi, Y.; Yelles, N.; Faye, P.; Cavelot, S.; Larcheveque, C.; Annonay, L.; Benhida, J.; Zahrate-Ghoul, A.; Hammal, S.; Belilita, R.; Lecronier, M.; Beurton, A.; Haudebourg, L.; Deleris, R.; Le Marec, J.; Virolle, S.; Nemlaghi, S.; Bureau, C.; Mora, P.; De Sarcus, M.; Clovet, O.; Duceau, B.; Grisot, P.H.; Pari, M.; Arzoine, J.; Clarac, U.; Faure, M.; Delemazure, J.; Decavele, M.; Morawiec, E.; Demoule, A.; Dres, M.; Vautier, M.; Allenbach, Y.; Benveniste, O.; Leroux, G.; Rigolet, A.; Guillaume-Jugnot, P.; Domont, F.; Desbois, A.C.; Comarmond, C.; Champtiaux, N.; Toquet, S.; Ghembaza, A.; Vieira, M.; Maalouf, G.; Boleto, G.; Ferfar, Y.; Charbonnier, F.; Aguilar, C.; Alby-Laurent, F.; Alyanakian, M-A.; Bakouboula, P.; Broissand, C.; Burger, C.; Campos-Vega, C.; Chavarot, N.; Choupeaux, L.; Elie, C.; Fournier, B.; Granville, S.; Issorat, E.; Rouzaud, C.; Vimpere, D.; Geri, G.; Derridj, N.; Sguiouar, N.; Meddah, H.; Djadel, M.; Chambrin-Lauvray, H.; Duclos-Vallée, J-C.; Saliba, F.; Sacleux, S-C.; Koumis, I.; Michot, J-M.; Stoclin, A.; Colomba, E.; Pommeret, F.; Willekens, C.; Da Silva, R.; Dejean, V.; Mekid, Y.; Ben-Mabrouk, I.; Pradon, C.; Drouard, L.; Camara-Clayette, V.; Morel, A.; Garcia, G.; Mohebbi, A.; Berbour, F.; Dehais, M.; Pouliquen, A-L.; Klasen, A.; Soyez-Herkert, L.; London, J.; Keroumi, Y.; Guillot, E.; Grailles, G.; El Amine, Y.; Defrancq, F.; Fodil, H.; Bouras, C.; Dautel, D.; Gambier, N.; Dieye, T.; Bienvenu, B.; Lancon, V.; Lecomte, L.; Beziriganyan, K.; Asselate, B.; Allanic, L.; Kiouris, E.; Legros, M-H.; Lemagner, C.; Martel, P.; Provitolo, V.; Ackermann, F.; Le Marchand, M.; Clan Hew Wai, A.; Fremont, D.; Coupez, E.; Adda, M.; Duée, F.; Bernard, L.; Gros, A.; Henry, E.; Courtin, C.; Pattyn, A.; Guinot, P-G.; Bardou, M.; Maurer, A.; Jambon, J.; Cransac, A.; Pernot, C.; Mourvillier, B.; Servettaz, A.; Deslée, G.; Wynckel, A.; Benoit, P.; Marquis, E.; Roux, D.; Gernez, C.; Yelnik, C.; Poissy, J.; Nizard, M.; Denies, F.; Gros, H.; Mourad, J-J.; Sacco, E.; Renet, S. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern. Med., 2021, 181(1), 32-40. doi: 10.1001/jamainternmed.2020.6820 PMID: 33080017
  49. Gordon, A.C.; Angus, D.C.; Derde, L.P.G. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med., 2021, 385(12), 1147-1149. doi: 10.1056/NEJMc2108482 PMID: 34407335
  50. Jeronimo, C.M.P.; Farias, M.E.L.; Val, F.F.A.; Sampaio, V.S.; Alexandre, M.A.A.; Melo, G.C.; Safe, I.P.; Borba, M.G.S.; Netto, R.L.A.; Maciel, A.B.S.; Neto, J.R.S.; Oliveira, L.B.; Figueiredo, E.F.G.; Oliveira Dinelly, K.M.; de Almeida Rodrigues, M.G.; Brito, M.; Mourão, M.P.G.; Pivoto João, G.A.; Hajjar, L.A.; Bassat, Q.; Romero, G.A.S.; Naveca, F.G.; Vasconcelos, H.L.; de Araújo Tavares, M.; Brito-Sousa, J.D.; Costa, F.T.M.; Nogueira, M.L.; Baía-da-Silva, D.C.; Xavier, M.S.; Monteiro, W.M.; Lacerda, M.V.G.; de Lemos Vasconcelos, A.; Praia Marins, A.F.; de Oliveira Trindade, A.; Mendes Záu, A.S.; de Oliveira, A.C.; Azevedo Furtado, A.C.; Coelho Rocha, A.P.; da Silva Souza, A.; de Souza Dias, A.; Belém, A.; dos Santos, A.G.R.; da Silva Sousa, A.M.; da Silva, B.F.; Franco, B.L.; da Silva, B.M.; da Costa, B.L.G.; Sato Barros do Amaral, C.M.S.; Judice, C.C.; de Morais, C.E.P.; Camilo, C.C.; Sena da Silva, D.S.; Gomes Duarte, D.C.; da Silva, E.G.N.; da Silva Lemos, E.; de Fátima Ponte Frota, E.; do Nascimento, E.F.; de Almeida, E.S.; Marques, E.A.; de Almeida, E.M.M.; da Silva, E.L.; dos Santos, E.G.; da Silva Oliveira, E.; Martins Shimizu, F.M.; de Souza, F.R.F.; da Silva do Vale, F.; dos Santos de Almeida Lima, F.; da Fonseca, F.H.J.; Fontenelle, F.A.; de Azevedo Furtado, F.; Da Silva Pereira, G.; Bezerra, G.A.; Maciel Salazar, G.K.; da Silva Pereira, H.; de Melo, H.F.; Oliveira, I.N.; Pereira Filho, I.V.; Gomes, J.V.; e Silva Rosa, J.; Lemos, J.M.; Brutus, J.N.; Pessoa, K.P.; Costa Rodrigues, L.D.; Barros Cirino, L.E.; Mourão Filho, L.F.; Moura, L.; Barbosa, L.R.P.; de Souza, L.P.; Oliveira, L.B.; de Lima Ferreira, L.C.; dos Santos, M.M.; da Silva, M.V.R.; Rodrigues, M.P.; de Menezes, M.T.; dos Santos Mota, M.M.; Freire, M.; Corrêa, N.F.; Rocha, N.M.; Bittencourt, N.; de Melo Silva, N.G.; de Oliveira Saraiva, P.; de Sousa Monteiro, Q.; dos Santos, R.T.; Freire, R.S.; de Araújo Pinto, R.A.; Ferreira, R.B.; de Lima, R.S.; de Melo, R.F.T.; Saenz, S.T.; Alvarez Fernandes, S.S.; Vítor-Silva, S.; de Oliveira, T.M.R.; Tavella, T.A.; Câmara, T.T.; Santos, T.C.; Pinto, T.S.; dos Santos, T.W.R.; do Nascimento, V.A.; Sousa, B.W.P.; de Melo, W.F.; Salgado, S.W.B. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A randomized, double-blind, phase IIb, placebo-controlled trial. Clin. Infect. Dis., 2021, 72(9), e373-e381. doi: 10.1093/cid/ciaa1177 PMID: 32785710
  51. Favalli, E.G.; Ingegnoli, F.; De Lucia, O.; Cincinelli, G.; Cimaz, R.; Caporali, R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun. Rev., 2020, 19(5), 102523. doi: 10.1016/j.autrev.2020.102523 PMID: 32205186
  52. Ma, J.; Muheem, A.; Rizvi, M. Coronavirus (COVID-19): History, current knowledge and pipeline medications. Int. J. Pharm., 2020, 4(1), 1-9. doi: 10.31531/2581-3080.1000140
  53. Pei, J.; Sekellick, M.J.; Marcus, P.I.; Choi, I.S.; Collisson, E.W. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. J. Interferon Cytokine Res., 2001, 21(12), 1071-1077. doi: 10.1089/107999001317205204 PMID: 11798465
  54. Chen, F.; Chan, K.H.; Jiang, Y.; Kao, R.Y.T.; Lu, H.T.; Fan, K.W.; Cheng, V.C.C.; Tsui, W.H.W.; Hung, I.F.N.; Lee, T.S.W.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol., 2004, 31(1), 69-75. doi: 10.1016/j.jcv.2004.03.003 PMID: 15288617
  55. Kuri, T.; Zhang, X.; Habjan, M.; Martínez-Sobrido, L.; García-Sastre, A.; Yuan, Z.; Weber, F. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. J. Gen. Virol., 2009, 90(11), 2686-2694. doi: 10.1099/vir.0.013599-0 PMID: 19625461
  56. Tan, E.L.C.; Ooi, E.E.; Lin, C.Y.; Tan, H.C.; Ling, A.E.; Lim, B.; Stanton, L.W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis., 2004, 10(4), 581-586. doi: 10.3201/eid1004.030458 PMID: 15200845
  57. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.H.; Albrecht, J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 2001, 358(9286), 958-965. doi: 10.1016/S0140-6736(01)06102-5 PMID: 11583749
  58. Deng, X.; Yu, X.; Pei, J. Regulation of interferon production as a potential strategy for COVID-19 treatment. arXiv, 2020, 2003.00751.
  59. Omrani, A.S.; Saad, M.M.; Baig, K.; Bahloul, A.; Abdul-Matin, M.; Alaidaroos, A.Y.; Almakhlafi, G.A.; Albarrak, M.M.; Memish, Z.A.; Albarrak, A.M. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect. Dis., 2014, 14(11), 1090-1095. doi: 10.1016/S1473-3099(14)70920-X PMID: 25278221
  60. Kalil, A.C. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA, 2020, 323(19), 1897-1898. doi: 10.1001/jama.2020.4742 PMID: 32208486
  61. Gautret, P.; Lagier, J.C.; Honoré, S.; Hoang, V.T.; Colson, P.; Raoult, D.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Dupont, H.T. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open label non-randomized clinical trial revisited. Int. J. Antimicrob. Agents, 2021, 57(1), 106243. doi: 10.1016/j.ijantimicag.2020.106243 PMID: 33408014
  62. Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Sevestre, J.; Mailhe, M.; Doudier, B.; Aubry, C.; Amrane, S.; Seng, P.; Hocquart, M.; Eldin, C.; Finance, J.; Vieira, V.E.; Tissot-Dupont, H.T.; Honoré, S.; Stein, A.; Million, M.; Colson, P.; La Scola, B.; Veit, V.; Jacquier, A.; Deharo, J.C.; Drancourt, M.; Fournier, P.E.; Rolain, J.M.; Brouqui, P.; Raoult, D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med. Infect. Dis., 2020, 34, 101663. doi: 10.1016/j.tmaid.2020.101663 PMID: 32289548
  63. Javelot, H.; El-Hage, W.; Meyer, G.; Becker, G.; Michel, B.; Hingray, C. COVID-19 and (hydroxy)chloroquine–azithromycin combination: Should we take the risk for our patients? Br. J. Clin. Pharmacol., 2020, 86(6), 1176-1177. doi: 10.1111/bcp.14335 PMID: 32350872
  64. Gbinigie, K.; Frie, K. Should azithromycin be used to treat COVID-19? A rapid review. BMJ open, 2020, 4(2), bjgpopen20X101094. doi: 10.3399/bjgpopen20X101094
  65. Andreani, J.; Le Bideau, M.; Duflot, I.; Jardot, P.; Rolland, C.; Boxberger, M.; Wurtz, N.; Rolain, J.M.; Colson, P.; La Scola, B.; Raoult, D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb. Pathog., 2020, 145, 104228. doi: 10.1016/j.micpath.2020.104228 PMID: 32344177
  66. Arikata, M.; Itoh, Y.; Shichinohe, S.; Nakayama, M.; Ishigaki, H.; Kinoshita, T.; Le, M.Q.; Kawaoka, Y.; Ogasawara, K.; Shimizu, T. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antiviral Res., 2019, 171, 104591. doi: 10.1016/j.antiviral.2019.104591 PMID: 31421167
  67. Takahashi, E.; Indalao, I.L.; Sawabuchi, T.; Mizuno, K.; Sakai, S.; Kimoto, T.; Kim, H.; Kido, H. Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. Comp. Immunol. Microbiol. Infect. Dis., 2018, 56, 6-13. doi: 10.1016/j.cimid.2017.11.002 PMID: 29406285
  68. Amsden, G. Erythromycin, clarithromycin, and azithromycin: Are the differences real? Clin. Ther., 1996, 18(1), 56-72. doi: 10.1016/S0149-2918(96)80179-2 PMID: 8851453
  69. Millán-Oñate, J.; Millan, W.; Mendoza, L.A.; Sánchez, C.G.; Fernandez-Suarez, H.; Bonilla-Aldana, D.K.; Rodríguez-Morales, A.J. Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Ann. Clin. Microbiol. Antimicrob., 2020, 19(1), 16. doi: 10.1186/s12941-020-00358-y PMID: 32331519
  70. Zhou, N.; Pan, T.; Zhang, J.; Li, Q.; Zhang, X.; Bai, C.; Huang, F.; Peng, T.; Zhang, J.; Liu, C.; Tao, L.; Zhang, H. Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biol. Chem., 2016, 291(17), 9218-9232. doi: 10.1074/jbc.M116.716100 PMID: 26953343
  71. Wang, Y.; Cui, R.; Li, G.; Gao, Q.; Yuan, S.; Altmeyer, R.; Zou, G. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res., 2016, 125, 1-7. doi: 10.1016/j.antiviral.2015.11.003 PMID: 26585243
  72. Baron, S.A.; Devaux, C.; Colson, P.; Raoult, D.; Rolain, J.M. Teicoplanin: An alternative drug for the treatment of COVID-19? Int. J. Antimicrob. Agents, 2020, 55(4), 105944. doi: 10.1016/j.ijantimicag.2020.105944 PMID: 32179150
  73. Ceccarelli, G.; Alessandri, F.; d’Ettorre, G.; Borrazzo, C.; Spagnolello, O.; Oliva, A.; Ruberto, F.; Mastroianni, C.M.; Pugliese, F.; Venditti, M. Is teicoplanin a complementary treatment option for COVID-19? The question remains. Int. J. Antimicrob. Agents, 2020, 56(2), 106029. doi: 10.1016/j.ijantimicag.2020.106029 PMID: 32454071
  74. Fredeking, T.; Zavala-Castro, J.; González-Martínez, P.; Moguel-Rodríguez, W.; Sanchez, E.; Foster, M.; Diaz-Quijano, F. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Patents Anti-Infect. Drug Disc., 2015, 10(1), 51-58. doi: 10.2174/1574891X10666150410153839 PMID: 25858261
  75. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet, 2020, 395(10229), 1033-1034. doi: 10.1016/S0140-6736(20)30628-0 PMID: 32192578
  76. Quartuccio, L.; Semerano, L.; Benucci, M.; Boissier, M.C.; De Vita, S. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine, 2020, 87(3), 191-193. doi: 10.1016/j.jbspin.2020.03.011 PMID: 32321634
  77. Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.; Zheng, M.; Chen, L.; Li, H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B, 2020, 10(5), 766-788. doi: 10.1016/j.apsb.2020.02.008 PMID: 32292689
  78. De Clercq, E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev. Anti Infect. Ther., 2006, 4(2), 291-302. doi: 10.1586/14787210.4.2.291 PMID: 16597209
  79. Wang, J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J. Chem. Inf. Model., 2020, 60(6), 3277-3286. doi: 10.1021/acs.jcim.0c00179 PMID: 32315171
  80. Thiem, U.; Heppner, H.J.; Pientka, L. Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging, 2011, 28(7), 519-537. doi: 10.2165/11591980-000000000-00000 PMID: 21721597
  81. Durojaiye, A.B.; Clarke, J.R.D.; Stamatiades, G.A.; Wang, C. Repurposing cefuroxime for treatment of COVID-19: A scoping review of in silico studies. J. Biomol. Struct. Dyn., 2021, 39(12), 4547-4554. doi: 10.1080/07391102.2020.1777904 PMID: 32538276
  82. Almutairi, A.S.; Abunurah, H.; Hadi Alanazi, A.; Alenezi, F.K.; Nagy, H.; Saad Almutairi, N.; Wells, M.; Alawam, A.; Alqahtani, M.M. The immunological response among COVID-19 patients with acute respiratory distress syndrome. J. Infect. Public Health, 2021, 14(7), 954-959. doi: 10.1016/j.jiph.2021.05.007 PMID: 34130119
  83. van Paassen, J.; Vos, J.S.; Hoekstra, E.M.; Neumann, K.M.I.; Boot, P.C.; Arbous, S.M. Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Crit. Care, 2020, 24(1), 696. doi: 10.1186/s13054-020-03400-9 PMID: 33317589
  84. Cheng, B.; Ma, J.; Yang, Y.; Shao, T.; Zhao, B.; Zeng, L. Systemic corticosteroid administration in coronavirus disease 2019 outcomes: An umbrella meta-analysis incorporating both mild and pulmonary fibrosis–manifested severe disease. Front. Pharmacol., 2021, 12, 670170. doi: 10.3389/fphar.2021.670170 PMID: 34122093
  85. Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L.C.; Faust, S.N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J.K.; Haynes, R.; Landray, M.J. Dexamethasone in hospitalized patients with covid-19. N. Engl. J. Med., 2021, 384(8), 693-704. doi: 10.1056/NEJMoa2021436 PMID: 32678530
  86. Kluge, S.; Janssens, U.; Welte, T.; Weber-Carstens, S.; Schälte, G.; Spinner, C.D.; Malin, J.J.; Gastmeier, P.; Langer, F.; Wepler, M.; Westhoff, M.; Pfeifer, M.; Rabe, K.F.; Hoffmann, F.; Böttiger, B.W.; Weinmann-Menke, J.; Kersten, A.; Berlit, P.; Haase, R.; Marx, G.; Karagiannidis, C. S2k-Leitlinie – empfehlungen zur stationären therapie von patienten mit COVID-19. Pneumologie, 2021, 75(2), 88-112. doi: 10.1055/a-1334-1925 PMID: 33450783
  87. Daminova, N. The European medicines agency ‘transparency’ policies, the CJEU and COVID-19: Do the CFREU provisions retain any relevance? MTA LAW WORKING PAPERS, 2021, 1(8), 1-32.
  88. Bartoletti, M.; Azap, O.; Barac, A.; Bussini, L.; Ergonul, O.; Krause, R.; Paño-Pardo, J.R.; Power, N.R.; Sibani, M.; Szabo, B.G.; Tsiodras, S.; Verweij, P.E.; Zollner-Schwetz, I.; Rodríguez-Baño, J. ESCMID COVID-19 living guidelines: Drug treatment and clinical management. Clin Microbiol Infect, 2022, 28(2), 222-238. doi: 10.1016/j.cmi.2021.11.007
  89. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y.; Song, J.; Wang, S.; Chao, Y.; Yang, Z.; Xu, J.; Zhou, X.; Chen, D.; Xiong, W.; Xu, L.; Zhou, F.; Jiang, J.; Bai, C.; Zheng, J.; Song, Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, 180(7), 934-943. doi: 10.1001/jamainternmed.2020.0994 PMID: 32167524
  90. Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223), 473-475. doi: 10.1016/S0140-6736(20)30317-2 PMID: 32043983
  91. Bahl, A.; Johnson, S.; Chen, N.W. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Intern. Emerg. Med., 2021, 16(6), 1593-1603. doi: 10.1007/s11739-021-02655-6 PMID: 33547620
  92. Bretagne, S.; Sitbon, K.; Botterel, F.; Dellière, S.; Letscher-Bru, V.; Chouaki, T.; Bellanger, A.P.; Bonnal, C.; Fekkar, A.; Persat, F.; Costa, D.; Bourgeois, N.; Dalle, F.; Lussac-Sorton, F.; Paugam, A.; Cassaing, S.; Hasseine, L.; Huguenin, A.; Guennouni, N.; Mazars, E.; Le Gal, S.; Sasso, M.; Brun, S.; Cadot, L.; Cassagne, C.; Cateau, E.; Gangneux, J.P.; Moniot, M.; Roux, A.L.; Tournus, C.; Desbois-Nogard, N.; Le Coustumier, A.; Moquet, O.; Alanio, A.; Dromer, F. COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: A retrospective multicenter observational cohort during the first French pandemic wave. Microbiol. Spectr., 2021, 9(2), e01138-21. doi: 10.1128/Spectrum.01138-21 PMID: 34668768
  93. Li, H.; Chen, C.; Hu, F.; Wang, J.; Zhao, Q.; Gale, R.P.; Liang, Y. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: A systematic review and meta-analysis. Leukemia, 2020, 34(6), 1503-1511. doi: 10.1038/s41375-020-0848-3 PMID: 32372026
  94. Budhathoki, P.; Shrestha, D.B.; Rawal, E.; Khadka, S. Corticosteroids in COVID-19: Is it rational? A systematic review and meta-analysis. SN Compr. Clin. Med., 2020, 2(12), 2600-2620. doi: 10.1007/s42399-020-00515-6 PMID: 33103063
  95. Day, M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ, 2020, 368, m1168. doi: 10.1136/bmj.m1168 PMID: 32205306
  96. Little, P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ, 2020, 368, m1185. doi: 10.1136/bmj.m1185 PMID: 32220865
  97. McManus, N.; Offman, R.; Oetman, J. Emergency department management of COVID-19: An evidence-based approach. West. J. Emerg. Med., 2020, 21(6), 32-44. doi: 10.5811/westjem.2020.8.48288 PMID: 33052814
  98. Amici, C.; Caro, A.D.; Ciucci, A.; Chiappa, L.; Castilletti, C.; Martella, V.; Decaro, N.; Buonavoglia, C.; Capobianchi, M.R.; Santoro, M.G. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir. Ther., 2006, 11(8), 1021-1030. doi: 10.1177/135965350601100803 PMID: 17302372
  99. Patel, A.B.; Verma, A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA, 2020, 323(18), 1769-1770. doi: 10.1001/jama.2020.4812 PMID: 32208485
  100. Sommerstein, R.; Kochen, M.M.; Messerli, F.H.; Gräni, C. Coronavirus disease 2019 (COVID-19): Do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J. Am. Heart Assoc., 2020, 9(7), e016509. doi: 10.1161/JAHA.120.016509 PMID: 32233753
  101. Warner, F.J.; Smith, A.I.; Hooper, N.M.; Turner, A.J. Angiotensin-converting enzyme-2: A molecular and cellular perspective. Cell. Mol. Life Sci., 2004, 61(21), 2704-2713. doi: 10.1007/s00018-004-4240-7 PMID: 15549171
  102. Dimitrov, D.S. The secret life of ACE2 as a receptor for the SARS virus. Cell, 2003, 115(6), 652-653. doi: 10.1016/S0092-8674(03)00976-0 PMID: 14675530
  103. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; Choe, H.; Farzan, M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426(6965), 450-454. doi: 10.1038/nature02145 PMID: 14647384
  104. Simmons, G.; Reeves, J.D.; Rennekamp, A.J.; Amberg, S.M.; Piefer, A.J.; Bates, P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci., 2004, 101(12), 4240-4245. doi: 10.1073/pnas.0306446101 PMID: 15010527
  105. Yeung, K.S.; Yamanaka, G.A.; Meanwell, N.A. Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Med. Res. Rev., 2006, 26(4), 414-433. doi: 10.1002/med.20055 PMID: 16521129
  106. Diaz, J.H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J. Travel Med., 2020, 27(3), taaa041. doi: 10.1093/jtm/taaa041 PMID: 32186711
  107. Rothan, H.A.; Byrareddy, S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun., 2020, 109, 102433. doi: 10.1016/j.jaut.2020.102433 PMID: 32113704
  108. Hussain, A.; Bhowmik, B.; do Vale Moreira, N.C. COVID-19 and diabetes: Knowledge in progress. Diabetes Res. Clin. Pract., 2020, 162, 108142. doi: 10.1016/j.diabres.2020.108142 PMID: 32278764
  109. Muniyappa, R.; Gubbi, S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am. J. Physiol. Endocrinol. Metab., 2020, 318(5), E736-E741. doi: 10.1152/ajpendo.00124.2020 PMID: 32228322
  110. Allard, R.; Leclerc, P.; Tremblay, C.; Tannenbaum, T.N. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care, 2010, 33(7), 1491-1493. doi: 10.2337/dc09-2215 PMID: 20587722
  111. Targher, G.; Mantovani, A.; Wang, X.B.; Yan, H.D.; Sun, Q.F.; Pan, K.H.; Byrne, C.D.; Zheng, K.I.; Chen, Y.P.; Eslam, M.; George, J.; Zheng, M.H. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab., 2020, 46(4), 335-337. doi: 10.1016/j.diabet.2020.05.001 PMID: 32416321
  112. Fadini, G.P.; Morieri, M.L.; Longato, E.; Avogaro, A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J. Endocrinol. Invest., 2020, 43(6), 867-869. doi: 10.1007/s40618-020-01236-2 PMID: 32222956
  113. Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; Zhao, L.; Fan, H.; Luo, S.; Hu, D. Diabetes is a risk factor for the progression and prognosis of COVID -19. Diabetes Metab. Res. Rev., 2020, 36(7), e3319. doi: 10.1002/dmrr.3319 PMID: 32233013
  114. Stoian, A.P.; Banerjee, Y.; Rizvi, A.A.; Rizzo, M. Diabetes and the COVID-19 pandemic: How insights from recent experience might guide future management. Metab. Syndr. Relat. Disord., 2020, 18(4), 173-175. doi: 10.1089/met.2020.0037 PMID: 32271125
  115. Bornstein, S.R.; Dalan, R.; Hopkins, D.; Mingrone, G.; Boehm, B.O. Endocrine and metabolic link to coronavirus infection. Nat. Rev. Endocrinol., 2020, 16(6), 297-298. doi: 10.1038/s41574-020-0353-9 PMID: 32242089
  116. Sardu, C.; D’Onofrio, N.; Balestrieri, M.L.; Barbieri, M.; Rizzo, M.R.; Messina, V.; Maggi, P.; Coppola, N.; Paolisso, G.; Marfella, R. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care, 2020, 43(7), 1408-1415. doi: 10.2337/dc20-0723 PMID: 32430456
  117. Solerte, S.B.; D’Addio, F.; Trevisan, R.; Lovati, E.; Rossi, A.; Pastore, I.; Dell’Acqua, M.; Ippolito, E.; Scaranna, C.; Bellante, R.; Galliani, S.; Dodesini, A.R.; Lepore, G.; Geni, F.; Fiorina, R.M.; Catena, E.; Corsico, A.; Colombo, R.; Mirani, M.; De Riva, C.; Oleandri, S.E.; Abdi, R.; Bonventre, J.V.; Rusconi, S.; Folli, F.; Di Sabatino, A.; Zuccotti, G.; Galli, M.; Fiorina, P. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: A multicenter, case-control, retrospective, observational study. Diabetes Care, 2020, 43(12), 2999-3006. doi: 10.2337/dc20-1521 PMID: 32994187
  118. Sun, Q.; Li, J.; Gao, F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J. Diabetes, 2014, 5(2), 89-96. doi: 10.4239/wjd.v5.i2.89 PMID: 24765237
  119. Salem, E.S.B.; Grobe, N.; Elased, K.M. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am. J. Physiol. Renal Physiol., 2014, 306(6), F629-F639. doi: 10.1152/ajprenal.00516.2013 PMID: 24452639
  120. Chen, Y.; Yang, D.; Cheng, B.; Chen, J.; Peng, A.; Yang, C.; Liu, C.; Xiong, M.; Deng, A.; Zhang, Y.; Zheng, L.; Huang, K. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care, 2020, 43(7), 1399-1407. doi: 10.2337/dc20-0660 PMID: 32409498
  121. Xian, H.; Liu, Y.; Nilsson, A.R.; Gatchalian, R.; Crother, T.R.; Tourtellotte, W.G.; Zhang, Y.; Aleman-Muench, G.R.; Lewis, G.; Chen, W. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity, 2021, 54(7), 1463-1477. e1411.. doi: 10.1016/j.immuni.2021.05.004
  122. Bramante, C.T.; Ingraham, N.E.; Murray, T.A.; Marmor, S.; Hovertsen, S.; Gronski, J.; McNeil, C.; Feng, R.; Guzman, G.; Abdelwahab, N.; King, S.; Tamariz, L.; Meehan, T.; Pendleton, K.M.; Benson, B.; Vojta, D.; Tignanelli, C.J. Metformin and risk of mortality in patients hospitalised with COVID-19: A retrospective cohort analysis. Lancet Healthy Longev., 2021, 2(1), e34-e41. doi: 10.1016/S2666-7568(20)30033-7 PMID: 33521772
  123. Lalau, J.D.; Al-Salameh, A.; Hadjadj, S.; Goronflot, T.; Wiernsperger, N.; Pichelin, M.; Allix, I.; Amadou, C.; Bourron, O.; Duriez, T.; Gautier, J.F.; Dutour, A.; Gonfroy, C.; Gouet, D.; Joubert, M.; Julier, I.; Larger, E.; Marchand, L.; Marre, M.; Meyer, L.; Olivier, F.; Prevost, G.; Quiniou, P.; Raffaitin-Cardin, C.; Roussel, R.; Saulnier, P.J.; Seret-Begue, D.; Thivolet, C.; Vatier, C.; Desailloud, R.; Wargny, M.; Gourdy, P.; Cariou, B. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab., 2021, 47(5), 101216. doi: 10.1016/j.diabet.2020.101216 PMID: 33309936
  124. Luo, P.; Qiu, L.; Liu, Y.; Liu, X.; Zheng, J.; Xue, H.; Liu, W.; Liu, D.; Li, J. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am. J. Trop. Med. Hyg., 2020, 103(1), 69-72. doi: 10.4269/ajtmh.20-0375 PMID: 32446312
  125. Apostolova, N.; Iannantuoni, F.; Gruevska, A.; Muntane, J.; Rocha, M.; Victor, V.M. Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions. Redox Biol., 2020, 34, 101517. doi: 10.1016/j.redox.2020.101517 PMID: 32535544
  126. Cheng, X.; Liu, Y.-M.; Li, H.; Zhang, X.; Lei, F.; Qin, J.-J.; Chen, Z.; Deng, K.-Q.; Lin, L.; Chen, M.-M. Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes. Cell metabolism, 2020, 32(4), 537-547. e533.. doi: 10.1016/j.cmet.2020.08.013
  127. Gao, Y.; Liu, T.; Zhong, W.; Liu, R.; Zhou, H.; Huang, W.; Zhang, W. Risk of metformin in patients with type 2 diabetes with COVID-19: A preliminary retrospective report. Clin. Transl. Sci., 2020, 13(6), 1055-1059. doi: 10.1111/cts.12897 PMID: 32955785
  128. Apicella, M.; Campopiano, M.C.; Mantuano, M.; Mazoni, L.; Coppelli, A.; Del Prato, S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol., 2020, 8(9), 782-792. doi: 10.1016/S2213-8587(20)30238-2 PMID: 32687793
  129. Katsiki, N.; Banach, M.; Mikhailidis, D. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch. Med. Sci., 2020, 16(3), 485-489. doi: 10.5114/aoms.2020.94503 PMID: 32399093
  130. Pratelli, A.; Colao, V. Role of the lipid rafts in the life cycle of canine coronavirus. J. Gen. Virol., 2015, 96(2), 331-337. doi: 10.1099/vir.0.070870-0 PMID: 25381058
  131. Schönbeck, U.; Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents? Circulation, 2004, 109(S21), II18-II26. doi: 10.1161/01.CIR.0000129505.34151.23 PMID: 15173059
  132. Baden, L.R.; Rubin, E.J. Covid-19 — the search for effective therapy. N. Engl. J. Med., 2020, 382(19), 1851-1852. doi: 10.1056/NEJMe2005477 PMID: 32187463
  133. Tay, M.Y.F.; Fraser, J.E.; Chan, W.K.K.; Moreland, N.J.; Rathore, A.P.; Wang, C.; Vasudevan, S.G.; Jans, D.A. Nuclear localization of dengue virus (DENV) 1–4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res., 2013, 99(3), 301-306. doi: 10.1016/j.antiviral.2013.06.002 PMID: 23769930
  134. Tu, Y.F.; Chien, C.S.; Yarmishyn, A.A.; Lin, Y.Y.; Luo, Y.H.; Lin, Y.T.; Lai, W.Y.; Yang, D.M.; Chou, S.J.; Yang, Y.P.; Wang, M.L.; Chiou, S.H. A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci., 2020, 21(7), 2657. doi: 10.3390/ijms21072657 PMID: 32290293
  135. Yang, S.N.Y.; Atkinson, S.C.; Wang, C.; Lee, A.; Bogoyevitch, M.A.; Borg, N.A.; Jans, D.A. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res., 2020, 177, 104760. doi: 10.1016/j.antiviral.2020.104760 PMID: 32135219
  136. Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 2020, 178, 104787. doi: 10.1016/j.antiviral.2020.104787 PMID: 32251768
  137. Lundberg, L.; Pinkham, C.; Baer, A.; Amaya, M.; Narayanan, A.; Wagstaff, K.M.; Jans, D.A.; Kehn-Hall, K. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res., 2013, 100(3), 662-672. doi: 10.1016/j.antiviral.2013.10.004 PMID: 24161512
  138. Guzzo, C.A.; Furtek, C.I.; Porras, A.G.; Chen, C.; Tipping, R.; Clineschmidt, C.M.; Sciberras, D.G.; Hsieh, J.Y.K.; Lasseter, K.C. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol., 2002, 42(10), 1122-1133. doi: 10.1177/009127002237994 PMID: 12362927
  139. Muñoz, J.; Ballester, M.R.; Antonijoan, R.M.; Gich, I.; Rodríguez, M.; Colli, E.; Gold, S.; Krolewiecki, A.J. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl. Trop. Dis., 2018, 12(1), e0006020. doi: 10.1371/journal.pntd.0006020 PMID: 29346388
  140. Bryant, A.; Lawrie, T.A.; Dowswell, T.; Fordham, E.J.; Mitchell, S.; Hill, S.R.; Tham, T.C. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am. J. Ther., 2021, 28(4), e434-e460. doi: 10.1097/MJT.0000000000001402 PMID: 34145166
  141. Kaur, H.; Shekhar, N.; Sharma, S.; Sarma, P.; Prakash, A.; Medhi, B. Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol. Rep., 2021, 73(3), 736-749. doi: 10.1007/s43440-020-00195-y PMID: 33389725
  142. Altay, O.; Mohammadi, E.; Lam, S.; Turkez, H.; Boren, J.; Nielsen, J.; Uhlen, M.; Mardinoglu, A. Current status of COVID-19 therapies and drug repositioning applications. iScience, 2020, 23(7), 101303. doi: 10.1016/j.isci.2020.101303 PMID: 32622261
  143. Gao, K.; Nguyen, D.D.; Chen, J.; Wang, R.; Wei, G.W. Repositioning of 8565 existing drugs for COVID-19. J. Phys. Chem. Lett., 2020, 11(13), 5373-5382. doi: 10.1021/acs.jpclett.0c01579 PMID: 32543196
  144. Pindiprolu, S.K.S.S.; Pindiprolu, S.H. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Med. Hypotheses, 2020, 140, 109765. doi: 10.1016/j.mehy.2020.109765 PMID: 32361588
  145. Gassen, N.C.; Papies, J.; Bajaj, T.; Emanuel, J.; Dethloff, F.; Chua, R.L.; Trimpert, J.; Heinemann, N.; Niemeyer, C.; Weege, F.; Hönzke, K.; Aschman, T.; Heinz, D.E.; Weckmann, K.; Ebert, T.; Zellner, A.; Lennarz, M.; Wyler, E.; Schroeder, S.; Richter, A.; Niemeyer, D.; Hoffmann, K.; Meyer, T.F.; Heppner, F.L.; Corman, V.M.; Landthaler, M.; Hocke, A.C.; Morkel, M.; Osterrieder, N.; Conrad, C.; Eils, R.; Radbruch, H.; Giavalisco, P.; Drosten, C.; Müller, M.A. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat. Commun., 2021, 12(1), 3818. doi: 10.1038/s41467-021-24007-w PMID: 34155207
  146. Stachulski, A.V.; Taujanskas, J.; Pate, S.L.; Rajoli, R.K.R.; Aljayyoussi, G.; Pennington, S.H.; Ward, S.A.; Hong, W.D.; Biagini, G.A.; Owen, A.; Nixon, G.L.; Leung, S.C.; O’Neill, P.M. Therapeutic potential of nitazoxanide: An appropriate choice for repurposing versus SARS-CoV-2? ACS Infect. Dis., 2021, 7(6), 1317-1331. doi: 10.1021/acsinfecdis.0c00478 PMID: 33352056
  147. Bobrowski, T.; Chen, L.; Eastman, R.T.; Itkin, Z.; Shinn, P.; Chen, C.Z.; Guo, H.; Zheng, W.; Michael, S.; Simeonov, A.; Hall, M.D.; Zakharov, A.V.; Muratov, E.N. Synergistic and antagonistic drug combinations against SARS-CoV-2. Mol. Ther., 2021, 29(2), 873-885. doi: 10.1016/j.ymthe.2020.12.016 PMID: 33333292
  148. Pascoalino, B.S.; Courtemanche, G.; Cordeiro, M.T.; Gil, L.H.V.G.; Freitas-Junior, L.H. Zika antiviral chemotherapy: Identification of drugs and promising starting points for drug discovery from an FDA-approved library. F1000 Res., 2016, 5, 2523. doi: 10.12688/f1000research.9648.1 PMID: 27909576
  149. Tonelli, M.; Simone, M.; Tasso, B.; Novelli, F.; Boido, V.; Sparatore, F.; Paglietti, G.; Pricl, S.; Giliberti, G.; Blois, S.; Ibba, C.; Sanna, G.; Loddo, R.; La Colla, P. Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. Bioorg. Med. Chem., 2010, 18(8), 2937-2953. doi: 10.1016/j.bmc.2010.02.037 PMID: 20359898
  150. Law, J.N.; Akers, K.; Tasnina, N.; Santina, C.M.D.; Deutsch, S.; Kshirsagar, M.; Klein-Seetharaman, J.; Crovella, M.; Rajagopalan, P.; Kasif, S.; Murali, T.M. Interpretable network propagation with application to expanding the repertoire of human proteins that interact with SARS-CoV-2. Gigascience, 2021, 10(12), giab082. doi: 10.1093/gigascience/giab082 PMID: 34966926
  151. Rainsford, K.D. Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology, 2006, 14(1-2), 2-9. doi: 10.1007/s10787-006-0002-5 PMID: 16835706
  152. Srinivasan, V.; Mohamed, M.; Kato, H. Melatonin in bacterial and viral infections with focus on sepsis: A review. Recent Pat. Endocr. Metab. Immune Drug Discov., 2012, 6(1), 30-39. doi: 10.2174/187221412799015317 PMID: 22264213
  153. Tan, D.X.; Korkmaz, A.; Reiter, R.J.; Manchester, L.C. Ebola virus disease: Potential use of melatonin as a treatment. J. Pineal Res., 2014, 57(4), 381-384. doi: 10.1111/jpi.12186 PMID: 25262626
  154. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res., 2007, 42(1), 28-42. doi: 10.1111/j.1600-079X.2006.00407.x PMID: 17198536
  155. Galano, A.; Tan, D.X.; Reiter, R.J. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J. Pineal Res., 2013, 54(3), 245-257. doi: 10.1111/jpi.12010 PMID: 22998574
  156. Xiao, J.; Shimada, M.; Liu, W.; Hu, D.; Matsumori, A. Anti-inflammatory effects of eplerenone on viral myocarditis. Eur. J. Heart Fail., 2009, 11(4), 349-353. doi: 10.1093/eurjhf/hfp023 PMID: 19213804
  157. Zhao, Y.; Ren, J.; Harlos, K.; Jones, D.M.; Zeltina, A.; Bowden, T.A.; Padilla-Parra, S.; Fry, E.E.; Stuart, D.I. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature, 2016, 535(7610), 169-172. doi: 10.1038/nature18615 PMID: 27362232
  158. Schwarz, S.; Wang, K.; Yu, W.; Sun, B.; Schwarz, W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res., 2011, 90(1), 64-69. doi: 10.1016/j.antiviral.2011.02.008 PMID: 21356245
  159. Ho, T.; Wu, S.; Chen, J.; Li, C.; Hsiang, C. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res., 2007, 74(2), 92-101. doi: 10.1016/j.antiviral.2006.04.014 PMID: 16730806

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2024